Myocardial injury biomarkers and their assays: advances, insights, and future directions
Both hs-cTn and hs-cMyC assays have shown equivalent diagnostic performance in the rule-out of myocardial infarction. Unfortunately, both are also plagued by the similar liabilities: decreased specificity for Type 1 AMI, and an inability to distinguish between types of myocardial injury. Proteolysis of each biomarker differs according to underlying pathology. Novel assays that quantify distinct forms could enhance patient triage.
Authors
- Michael Marber (ORCID: https://orcid.org/0000-0002-3463-7128)
- Samuel McGrath (ORCID: https://orcid.org/0000-0003-0109-1509)
- Bashir Alaour (ORCID: https://orcid.org/0000-0001-5604-1096)
Institutions
- King's College London (GB)
Publication Details
- Journal
- Expert Review of Cardiovascular Therapy
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1080/14779072.2025.2586669
- Primary Topic
- Acute Myocardial Infarction Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00